Pediatric patients who adopted and sustained a CD exclusion diet achieved clinical remission and reported improvement in clinical symptoms and fecal calprotectin.
Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...
A new study links mitochondrial dysfunction to Crohn’s disease, shifting how scientists approach treatment and opening doors ...
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...
Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.
Tampa Bay Lightning forward Michael Eyssimont was diagnosed with Crohn's disease eight years ago at the age of 21. Since then, he's found a way to manage the disease with treatment and a strict diet.
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Researchers at the University of Gothenburg have uncovered a critical mechanism that may pave the way for innovative ...
A surgical approach pioneered in Ireland could have a global impact on the treatment of Crohn's disease.
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results